|
Canada-0-LOGISTICS कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Mechanism of Action (MoA) | TRYNGOLZA® (olezarsen) Injection
TRYNGOLZA is a GaINAc-conjugated antisense oligonucleotide, or ASO, that inhibits the production of apoC-III, a key regulator of TRL metabolism and hepatic clearance The conjugation of GalNAc to the ASO enables targeted delivery to the liver, where apoC-III messenger RNA, or mRNA, is generated
- Tryngolza: Package Insert Prescribing Information MOA
12 1 Tryngolza Mechanism of Action Olezarsen is an ASO-GalNAc 3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein
- label - accessdata. fda. gov
TRYNGOLZA is a prescription medicine used along with diet to reduce triglycerides (fat in the blood) in the treatment of adults with a condition that keeps the body from breaking down fats called
- DailyMed - TRYNGOLZA- olezarsen sodium injection, solution
TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)
- How TRYNGOLZA® Works | TRYNGOLZA® (olezarsen) Injection
After binding to the cell, TRYNGOLZA is brought into the cell and the ASO binds to the apoC-III mRNA The binding of TRYNGOLZA leads to the breakdown of the apoC-III mRNA and reduces apoC-III in the blood, resulting in reduced triglyceride levels
- Tryngolza, INN-Olezarsen
Tryngolza is a medicine that changes the way in which the body breaks down fats (a so-called lipid-lowering medicine) It contains the active substance olezarsen
- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include . . .
12 1 Mechanism of Action Olezarsen is an ASO-GalNAc3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein Reduction of apoC-III protein leads to increased clearance of plasma TG and VLDL
- Tryngolza (olezarsen) dosing, indications, interactions, adverse . . .
Olezarsen is a GalNAc 3 -conjugated antisense oligonucleotide that reduces apolipoprotein C-III (APOC3) production by binding to APOC3 mRNA and inducing its degradation Elevated levels of APOC3
- Olezarsen - Wikipedia
By reducing serum apoC-III, olezarsen increases clearance of plasma triglycerides [2] The most common side effects include injection site reactions, low platelet counts, and joint pain [5]
- TRYNGOLZA Solution for injection Pharmacology - MPI, US: SPL PLR . . .
Mechanism of Action Olezarsen is an ASO-GalNAc 3 conjugate that binds to apoC-III mRNA leading to mRNA degradation and resulting in a reduction of serum apoC-III protein
|
|